Free shipping on all orders over $ 500

CU-CPT22

Cat. No. M8408
CU-CPT22 Structure
Size Price Availability Quantity
2mg USD 70  USD70 In stock
5mg USD 100  USD100 In stock
10mg USD 170  USD170 In stock
25mg USD 320  USD320 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2. CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM. CU-CPT22 can compete with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with high inhibitory activity and specificity. The inhibition constant (Ki) is 0.41 ± 0.07 µM. CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. It has no significant cytotoxicity at various concentrations up to 100 µM in RAW 264.7 cells using MTT assay. Kinase profiling shows that CU-CPT22 demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4). CU-CPT22 suppresses TLR1/2-mediated inflammation response. It inhibits about 60% of TNF-α and 95% of IL-1β at 8 µM in the RAW 264.7 cells.

Protocol (for reference only)
Cell Experiment
Cell lines MUTZ-3-derived Langerhans cells (MUTZ-LCs)
Preparation method MUTZ-LCs are seeded in alpha medium without supple-ments and exposed to different microbial and pro-inflammatorystimuli for 24 h (2.5 × 105 cells/ml): 1 μg/ml Pam3CSK4, 1 μg/mlPam2CSK4, 1 μg/ml poly(A:U), 1 μg/ml poly(I:C), 1 μg/ml ultrapurelipopolysaccharide (LPS) from Escherichia coli serotype 0111:B4, 50 ng/ml rh-TNF-α, 30 ng/ml rh-IL-1β, or a cytokine maturation cocktail(CMC) consisting of 50 ng/ml rh-TNF-α, 25 ng/ml rh-IL-1β,100 ng/ml rh-IL-6 and 1 μg/ml PGE2. Cytokines produced in E. coli, contained low endotoxinlevels (≤1.0 EU/μg cytokine) as determined by Limulus Amebo-cyte Lysate (LAL) assay. As control MUTZ-LCs (2.5 × 105 cells/ml) are maintained for 24 hor 48 h in alpha medium only. The TLR2/1 antagonist CU-CPT22 is applied 1 h before stimulation with Pam3CSK4 and Pam2CSK4, respectively.
Concentrations 10 and 25 μM
Incubation time 1 h Method:
Animal Experiment
Animal models Male LETO and OLETF rats
Formulation vehicle (75% DMSO plus 25% distilled water)
Dosages 3 mg/kg
Administration intraperitoneally
Chemical Information
Molecular Weight 362.37
Formula C19H22O7
CAS Number 1416324-85-0
Solubility (25°C) DMSO 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Kouhei Ohno, et al. Am J Physiol Heart Circ Physiol . Diabetes increases the susceptibility to acute kidney injury after myocardial infarction through augmented activation of renal Toll-like receptors in rats

[2] Kui Cheng, et al. Angew Chem Int Ed Engl. Discovery of small-molecule inhibitors of the TLR1/TLR2 complex

Related TLR Products
Kdo2-Lipid A ammonium

Kdo2-Lipid A ammonium is a chemically defined lipopolysaccharide (LPS) with endotoxic activity equivalent to LPS.Kdo2-Lipid A ammonium is highly selective for TLR4 and stimulates the release of TNF and PGE2.

PSMα3

PSMα3 is a peptide for manipulating DCs to become tolerogenic for DC vaccination strategies.

Pam2CSK4

Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist.

MAPK-IN-1

MAPK-IN-1 is a MAPK signaling pathway inhibitor.

Cobitolimod

Cobitolimod is a first-of-its-kind (first-in-class), synthetic oligodeoxynucleotide (ODN) containing unmethylated CpG motifs that activates TLR9 in specific cells, including intestinal T and B lymphocytes as well as antigen-presenting cells (APCs), and can be used in studies related to inflammatory bowel disease (IBD).

  Catalog
Abmole Inhibitor Catalog




Keywords: CU-CPT22 supplier, TLR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.